934 results on '"Friberg, Lena E"'
Search Results
152. Reply to Wilson et al
153. A Semi-Mechanistic Model of CP-690,550-Induced Reduction in Neutrophil Counts in Patients With Rheumatoid Arthritis
154. Erratum to: Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen
155. Model-Based Neutrophil-Guided Dose Adaptation in Chemotherapy: Evaluation of Predicted Outcome with Different Types and Amounts of Information
156. A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients
157. A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6
158. Model-Based Drug Development in Pulmonary Delivery : Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection
159. Model-based drug development in pulmonary delivery: pharmacokinetic analysis of novel drug candidates for treatment of Pseudomonas aeruginosa lung infection
160. A Pharmacokinetic-Pharmacodynamic model built on in vitro data predicts the antibacterial effect of polymyxin B against Klebsiella pneumoniae in vivo
161. Application of pharmacokinetic-pharmacodynamic modeling in management of QT abnormalities after citalopram overdose. Reply to A. Manini
162. Reply to Dr. Mégarbane et al. regarding “Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose”
163. Human methyl parathion poisoning
164. Pharmacokinetic–pharmacodynamic modelling of QT interval prolongation following citalopram overdoses
165. Pharmacokinetic–pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model
166. Pharmacokinetic/Pharmacodynamic Modelling in Oncological Drug Development
167. Piperacillin pharmacokinetics and target attainment in children with cancer and fever : Can we optimize our dosing strategy?
168. Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy : the impact of body weight and target on an optimal dosing regimen
169. Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis
170. Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer
171. Association between paclitaxel clearance and tumor response in patients with esophageal cancer
172. Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes
173. Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs
174. From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics.
175. Optimization of Piperacillin-Tazobactam Treatment in Pediatric Oncology Patients with Fever - a Prospective Study':Presented as an oral presentation at the NOPHO 36th Annual Meeting | NOBOS 12th Biannual Meeting in Vilnius, Lithuania on 1-6 June, 2018 on Sunday 03-06 at 15:45-16:00
176. Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen
177. Effects of cladribine tablets on heart rate, atrio‐ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis
178. Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy?
179. Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer
180. Model-Based Drug Development in Pulmonary Delivery: Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection
181. Population Pharmacokinetics of Piperacillin in Sepsis Patients : Should Alternative Dosing Strategies Be Considered?
182. A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat
183. Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations
184. Reply to Prim et al., 'Is Colistin Susceptibility Testing Finally on the Right Track?'
185. Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment
186. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria : an open-label, randomised controlled trial
187. Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli
188. Advanced methods for dose and regimen finding during drug development:Summary of the EMA /EFPIA workshop on dose finding (London 4-5 December 2014)
189. Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia
190. Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration
191. Erratum to: Warfarin dose prediction in children using pharmacometric bridging – comparison with published pharmacogenetic dosing algorithms
192. A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients
193. A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat
194. Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?
195. Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment
196. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
197. Reply to Prim et al., “Is Colistin Susceptibility Testing Finally on the Right Track?”
198. Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli
199. Colistin Is Extensively Lost during Standard In Vitro Experimental Conditions
200. Advanced Methods for Dose and Regimen Finding During Drug Development : Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.